{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-221527","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.497307+00:00","generated_at":"2026-05-17T05:22:10.183795+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zelicapavir shows 6.7-day symptom resolution improvement in high-risk RSV adults","bullets":["6.7-day faster complete resolution of all 13 RSV symptoms in HR3 population (COPD/CHF/age≥75); 7.2-day improvement in total RiiQ.","Hospitalization rate 1.7% for zelicapavir vs 5.0% placebo; 2-day faster PGI-S improvement (p<0.05).","Robust antiviral effect: 4–5 day faster undetectable viral load; 23.5% vs 10.0% undetectable at end of treatment (p=0.0198).","Favorable safety: no treatment discontinuations; most common AEs diarrhea (3.3%) and asthma (2.5%).","Primary endpoint (time to mild LRTD symptoms) not met; data inform Phase 3 design and registrational endpoints."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-221527","json":"https://secwatch.observer/filing/0001193125-25-221527.json","markdown":"https://secwatch.observer/filing/0001193125-25-221527.md","text":"https://secwatch.observer/filing/0001193125-25-221527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000119312525221527/0001193125-25-221527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000119312525221527/d16388d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:22:10.183795+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}